KalVista Pharmaceuticals (KALV) Competitors $8.90 -0.06 (-0.67%) (As of 10:25 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends KALV vs. ALIM, ABUS, BYSI, MGTA, BCRX, KNSA, TVTX, SYRE, NTLA, and PRAXShould you be buying KalVista Pharmaceuticals stock or one of its competitors? The main competitors of KalVista Pharmaceuticals include Alimera Sciences (ALIM), Arbutus Biopharma (ABUS), BeyondSpring (BYSI), Magenta Therapeutics (MGTA), BioCryst Pharmaceuticals (BCRX), Kiniksa Pharmaceuticals (KNSA), Travere Therapeutics (TVTX), Spyre Therapeutics (SYRE), Intellia Therapeutics (NTLA), and Praxis Precision Medicines (PRAX). These companies are all part of the "medical" sector. KalVista Pharmaceuticals vs. Alimera Sciences Arbutus Biopharma BeyondSpring Magenta Therapeutics BioCryst Pharmaceuticals Kiniksa Pharmaceuticals Travere Therapeutics Spyre Therapeutics Intellia Therapeutics Praxis Precision Medicines KalVista Pharmaceuticals (NASDAQ:KALV) and Alimera Sciences (NASDAQ:ALIM) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, community ranking, profitability and risk. Do insiders & institutionals have more ownership in KALV or ALIM? 99.8% of Alimera Sciences shares are held by institutional investors. 10.5% of KalVista Pharmaceuticals shares are held by company insiders. Comparatively, 31.4% of Alimera Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the MarketBeat Community believe in KALV or ALIM? Alimera Sciences received 19 more outperform votes than KalVista Pharmaceuticals when rated by MarketBeat users. However, 74.39% of users gave KalVista Pharmaceuticals an outperform vote while only 55.80% of users gave Alimera Sciences an outperform vote. CompanyUnderperformOutperformKalVista PharmaceuticalsOutperform Votes33774.39% Underperform Votes11625.61% Alimera SciencesOutperform Votes35655.80% Underperform Votes28244.20% Which has more volatility and risk, KALV or ALIM? KalVista Pharmaceuticals has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500. Comparatively, Alimera Sciences has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500. Is KALV or ALIM more profitable? KalVista Pharmaceuticals has a net margin of 0.00% compared to Alimera Sciences' net margin of -14.74%. Alimera Sciences' return on equity of -33.70% beat KalVista Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets KalVista PharmaceuticalsN/A -97.37% -82.39% Alimera Sciences -14.74%-33.70%-9.63% Does the media refer more to KALV or ALIM? In the previous week, KalVista Pharmaceuticals had 7 more articles in the media than Alimera Sciences. MarketBeat recorded 7 mentions for KalVista Pharmaceuticals and 0 mentions for Alimera Sciences. KalVista Pharmaceuticals' average media sentiment score of 0.32 beat Alimera Sciences' score of 0.00 indicating that KalVista Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment KalVista Pharmaceuticals Neutral Alimera Sciences Neutral Which has higher valuation and earnings, KALV or ALIM? Alimera Sciences has higher revenue and earnings than KalVista Pharmaceuticals. Alimera Sciences is trading at a lower price-to-earnings ratio than KalVista Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKalVista PharmaceuticalsN/AN/A-$126.64M-$3.53-2.52Alimera Sciences$99.68M2.91-$20.13M-$1.57-3.53 Do analysts rate KALV or ALIM? KalVista Pharmaceuticals currently has a consensus price target of $26.00, suggesting a potential upside of 192.13%. Alimera Sciences has a consensus price target of $8.00, suggesting a potential upside of 44.40%. Given KalVista Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe KalVista Pharmaceuticals is more favorable than Alimera Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score KalVista Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Alimera Sciences 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryAlimera Sciences beats KalVista Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Ad WealthPressThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here Get KalVista Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KALV vs. The Competition Export to ExcelMetricKalVista PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$384.66M$6.48B$5.07B$8.80BDividend YieldN/A8.11%4.99%4.07%P/E Ratio-2.524.9789.5613.60Price / SalesN/A371.451,224.8087.40Price / CashN/A52.5939.4536.27Price / Book1.8310.306.976.33Net Income-$126.64M$153.61M$119.04M$225.93M7 Day Performance-9.18%-1.73%-1.78%-0.96%1 Month Performance-27.76%-7.26%-3.59%1.06%1 Year Performance15.14%31.10%31.64%26.59% KalVista Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KALVKalVista Pharmaceuticals3.7142 of 5 stars$8.90-0.7%$26.00+192.1%+9.1%$384.66MN/A-2.52150Insider TradeNews CoverageALIMAlimera SciencesN/A$5.54flat$8.00+44.4%N/A$290.24M$99.68M-3.53150ABUSArbutus Biopharma2.7999 of 5 stars$3.45+0.3%$5.50+59.4%+87.0%$653.74M$18.14M-8.0073Analyst ForecastBYSIBeyondSpringN/A$1.70-0.6%N/A+86.1%$66.35M$1.75M0.0080MGTAMagenta Therapeutics0.8555 of 5 stars$0.70-7.7%N/A+0.0%$42.44MN/A0.0067Gap DownBCRXBioCryst Pharmaceuticals4.2315 of 5 stars$7.16-1.9%$15.60+117.9%+35.2%$1.48B$331.41M0.00530Short Interest ↓KNSAKiniksa Pharmaceuticals1.9939 of 5 stars$20.73-2.3%$36.60+76.6%+33.9%$1.50B$270.26M0.00220TVTXTravere Therapeutics3.0581 of 5 stars$18.36+2.8%$22.62+23.2%+210.6%$1.43B$145.24M0.00460SYRESpyre Therapeutics2.3417 of 5 stars$27.18-1.2%$48.57+78.7%N/A$1.40B$890,000.000.00100News CoverageNTLAIntellia Therapeutics4.5424 of 5 stars$13.54+3.2%$54.94+305.7%-56.7%$1.38B$36.28M-2.58600Analyst ForecastAnalyst RevisionPRAXPraxis Precision Medicines1.7647 of 5 stars$73.71+0.0%$146.33+98.5%+299.3%$1.37B$2.45M0.00110 Related Companies and Tools Related Companies ALIM Alternatives ABUS Alternatives BYSI Alternatives MGTA Alternatives BCRX Alternatives KNSA Alternatives TVTX Alternatives SYRE Alternatives NTLA Alternatives PRAX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KALV) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KalVista Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KalVista Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
